Endo, Novartis begin Voltaren gel licensing deal

Share this article:
Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.

Endo said it expects to commercialize Voltaren Gel initially using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May, with an additional 275 contract sales representatives targeting primary care physicians who prescribe NSAIDs and Cox-2s.
Voltaren Gel received FDA approval in October 2007, being granted marketing exclusivity in the US as a prescription medicine at least until October 2010.

Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million.

Under the terms of the five-year agreement with Novartis, Endo will make an upfront cash payment of $85 million.

Novartis is also eligible to receive a one-time milestone payment of $25 million if annual sales exceed $300 million. Under the deal, Novartis will receive royalties on the net sales of Voltaren Gel in the US and will supply this product to Endo.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.